Tarsus Pharmaceuticals
TARS
148 hedge funds and large institutions have $1.09B invested in Tarsus Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 67 increasing their positions, 41 reducing their positions, and 34 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 41
1.19% more ownership
Funds ownership: 104.86% → 106.05% (+1.2%)
6% less funds holding
Funds holding: 157 → 148 (-9)
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
24% less capital invested
Capital invested by funds: $1.43B → $1.09B (-$340M)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
90% less call options, than puts
Call options by funds: $2.26M | Put options by funds: $22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$35.8M |
| 2 |
BlackRock
New York
|
+$20.6M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$15.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$12.8M |
| 5 |
Millennium Management
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$55.1M |
| 2 |
Morgan Stanley
New York
|
-$17.3M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$17.1M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$14.4M |
| 5 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
-$13.2M |
TARS Hedge Fund Activity: Q2 2024 in Review
148 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q2 2024, worth a combined $1.09B — down 24% from $1.43B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of TARS and 26 opened new positions — a net loss of 8 holders — while 41 trimmed existing stakes and 67 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $35.8M. The largest seller was Cormorant Asset Management, cutting an estimated $55.1M.
- 148 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q2 2024, down from 157 in Q1 2024.
- Funds reported $1.09B of Tarsus Pharmaceuticals stock for Q2 2024, down 24% quarter-over-quarter.
- 26 funds opened new Tarsus Pharmaceuticals positions in Q2 2024 and 34 closed out, a net change of -8 holders.
- The largest Tarsus Pharmaceuticals buyer in Q2 2024 was Assenagon Asset Management, an estimated $35.8M added.
- The largest Tarsus Pharmaceuticals seller in Q2 2024 was Cormorant Asset Management, an estimated $55.1M sold.
Based on aggregated 13F filings for Q2 2024.